| Panel | ||||||||
|---|---|---|---|---|---|---|---|---|
| ||||||||
7Instructions: Use the pencil icon in the top right to edit the form below. ↗️ Remember to push PUBLISH when you are done to save your work. |
...
Treatment Intensification (Combination Therapy) Plan | Treatment Intensification (Combination Therapy) Actual |
Describe Intervention (Select ONE; useBPAA Project Roadmap for ideas on evidence-based strategies) Chosen intervention:
Patients with uncontrolled hypertension Patients with uncontrolled hypertension: Not on a guideline-recommended therapy On mono-therapy Patients with undiagnosed hypertension
Utilize our new population health software, Azara, to create/disseminate a health registry, or tracking type, which will be accessible at point of care for clinical decision making. Design new Million Hearts care gap dashboard and reports to address therapeutic inertia and control rates. Continue to train clinicians on guideline-supported treatment algorithm (AMA Hypertension Treatment algorithm). Continue SMBP program to support clinical decision making to address inertia and intensification. | Chosen Intervention: Develop population health registries and point of care clinical decision support Date when implemented: January 1, 2024 Updates: The process to transfer to connect and migrate our historical and current EMR Data into Azara began in October 2023 12/19 - on pause due to Azara implementation, will use for pre-visit planning and distribute to care teams in the morning, interest of residents in participating and they might be able to do a deep dive in chart reviews but also potential of using Azara instead of having to do individual chart reviews 2/20: Mike is meeting with the Azara team on 2/20 to receive training on registries. An alert for patients with stage 1 HTN in the pre visit planning form has been created (Guideline Therapy). Replicating the dashboard done for other participants in the Million hearts programs. movement of data to Azara has gone well. staff are asking for PVP and huddle sheets - are used to this! Excited about this as well as SMBP referrals and the potential utilization of Azara. 4/9: Referral to clinical pharmacist for medication titration as per protocol. Implementation Strategy for One Intervention (4/30) Strategy Name: Data-Driven Clinical Decision Support to guide Treatment Intensification/SMBP Strategy description (including who is the focus/target of the intervention): Developed population health registries and point of care clinical decision support to identify AA patients with uncontrolled hypertension and Monotherapy/Non Guideline-recommended therapy for Treatment Intensification/SMBP Who enacts the strategy: Clinical Care Team (Providers, RN, MA, BHC), SMBP Trainers (Program Manager, Patient Engagement Specialist, Community Health Worker and QI Coordinator) What specific actions, steps, or processes need to be enacted before the intervention can be implemented (e.g., enacting a new policy, developing a workflow, building a new report)?: Develop SMBP enrollment workflow, train QI staff on new population health software, build registry, integrate clinical decision support into SMBP workflow. When is the strategy used (e.g., during each patient visit, during monthly QI meetings)?: Daily as it is a designed to be POC, weekly for pre-visit planning, and monthly during QI meetings. What is the dose of the strategy (e.g., one 3-hour training)?: Variable (daily workflow and monthly planning meetings). |
Reach (#/% patients – or providers, for provider-facing interventions – who participated in intervention) | |
Reach of implementers/providers? Planned: Intervention to be implemented across the organization. | Reach of implementers/providers? Actual: Intervention has reached nearly all service providers, including Family Health, Internist, OB/GYN, Behavioral Health (LCSW), and Social Services; engaging these staff in various roles of our program. |
Reach of patients (# of patients receiving treatment intensification)? Planned: All uncontrolled hypertensive patients - approximately 500 AA Uncontrolled HTN patients will be part of the registry*. (*AA Pts with last BP >140/90 during the reporting period-as of 6/30/23: 537)
| Reach of patients: The intervention was applied to the majority of our MH PTS: Utilize Data-Driven Clinical Decision Support to guide Treatment Intensification/SMBP Following AMA MAP Algorithm leading to Treatment Intensification Enrollment in SMBP Program - Intensify Medication, Educate Therapeutic Lifestyle Changes (Diet, Exercise, Stress Mngmnt) |
Efficacy (Impact of intervention on important outcomes) | |
How will you measure that your intervention is working? Azara Dashboard and Analytic Report designed for chosen MH Intervention | Were you able to accurately measure how your intervention was working? Yes - Utilizing Population Health Tool-Azara |
What outcomes do you expect? A 10% increase in HTN Control with AA patients. A 20% decrease in # AA pts w/ uncontrolled HTN on Monotherapy A 10% decrease in # AA pts w/ uncontrolled HTN on No Therapy | What outcomes have you seen? Actual: Trailing Year July 23 (TY_April23) vs. TY_April24 - Green (met goal); Yellow (approached goal) MH Control Rate: TY_April23: 46.56% (671/1441) vs. TY_April24: 51.04% (808/1583) MH Uncontrolled No Anti Htn. Meds: TY_April23: 13.60% (84/619) vs. TY_April24: 12.4% (86/692) MH Uncontrolled Monotherapy: TY_April23: 34.2% (212/619) vs. TY_April24: 31.4% (217/692) MH Guideline Therapy: TY_April23: 74% TY_April24: 72.4% |
How will you ensure your intervention will be effective for your target population? Utilize a PDSA to review the workflow designed to best utilize the population health registries and point of care clinical decision support to identify AA pts w/ uncontrolled on Monotherapy or No Therapy. | Did your intervention reach the target population? YES TBD |
What unintended consequences or outcomes might there be? Patients might experience difficulty tolerating a particular combination of hypertension medications during the process of intensification. This could lead to reluctance from both patients and healthcare providers in considering the use of a second agent in the future. | What unintended outcomes did you experience? Some documented side effects of intensification were observed in the chart during this program year, ex: not tolerating ACE or CCB due to side effects. |
Adoption (#/% and representativeness of staff and sites who implemented the intervention) How did clinicians respond to interventions to intensify medication more rapidly/address therapeutic inertia? | |
Who will deliver the intervention (actually do the work)? Include staff and sites, if applicable. Clinical Care Team and Office Manager at each site; Performance Improvement Coordinator, Program Coordinator and Patient Engagement Specialist. | Who delivered the intervention? Family Health, Internist, OB/GYN, Behavioral Health (LCSW), and Social Services; engaging these staff in various roles of our program. Did they have the skills and time needed to complete the intervention? YES Second Year and Third Year Family Medicine Residents did their Quality Improvement projects on our SMBP program, as well as championing the Million Hearts Public Health Intern performed a Data Analysis of our SMBP Program. Did they have the skills and time needed to complete the intervention? YES |
How will you know if clinicians/care teams/sites used the intervention? Dashboard, reports and chart reviews performed per PDSA | What proportion of the planned staff/sites implemented the intervention? 100% Were there any differences between care teams/sites who adopted the intervention best vs. others who did not (e.g., differences in staff types, capacity, etc.)? |
Implementation Fidelity (How closely the staff/sites followed the intervention design, delivered it as intended – also called fidelity to the intervention) | |
How will you know what adaptations or modifications were made during the intervention? Tracking and reviewing the intervention PDSA | How did you track modifications during the intervention? |
What might be some of the possible obstacles to consistent implementation? Dissemination and adoption of the registry at the point of care. Provider reluctance to intensify treatment, patient reluctance to intensify due to fear of side effects. Provider workload, issues addressing multiple problems in one visit. | What were the barriers to consistent intervention implementation? |
What costs and resources (including time and burden, not just money) need to be considered? SMBP cuffs are an integral part of our approach but are a limited resource, how do we sustain access? Lack of insurance coverage for bluetooth enabled BP cuffs causing ChesPenn to take on that additional cost. Issues with reimbursement for clinical pharmacists. *Note: Keystone First pilot program does provide care coordination reimbursement for patients enrolled in SMBP; funds are used to support the overall program. | What costs and resources (including time and burden, not just money) need to be considered? |
How closely did the staff/sites follow the intervention design and deliver as intended? Check all that apply:
Modifications made and other notes: | |
Maintenance (Extent to which intervention is part of routine practices and protocols) | |
What reinforcements will you put in place to sustain the intervention, if effective?
Explain: If intervention demonstrates a positive outcome we will reinforce by continuing our iterative PDSA cycle, documenting policies/protocols, and include in our Quality Improvement plan approved annually by our board.. | What reinforcements did you put into place to sustain the intervention?
Explain: |
How will you spread your intervention and lessons learned? Through our MH network, Organizational QI mtgs and monthly staff meetings. AMA MAP hypertension protocol will be included in the ChesPenn quality improvement policy which is approved by the board annually. | How will you spread your intervention and lessons learned? |
We will look to continue the Keystone First pilot program and seek other opportunities or partners to secure sustainability including clinical pharmacy reimbursement. | What are likely modifications or adaptations that will need to be made to sustain the intervention over time (e.g., lower cost, different staff, reduced intensity, different settings)? |
...